



Solagran Limited

Solagran Limited
ACN 002 592 396
98-106 Moray Street
Melbourne, 3205
Victoria
Australia
Tel 61 3 9820 2699
Fax 61 3 9820 3155

18 March 2015

ASX Announcement

Key United States Patent Granted for Solagran's Core Production Technology

Melbourne, Australia: Solagran Limited (ASX: SLA) announces that a key patent protecting the Company's core production technology for the manufacture of Bioeffectives®, including polyprenols / "Bioeffective R" (the major component of Ropren®), has issued in the United States.

United States Patent No. 8,969,517 entitled "Method for Processing Vegetable Raw Materials" has corresponding patents already granted in Australia, Russia, Canada, Indonesia and Latvia, and applications have also been filed in selected other jurisdictions.

Dr Vagif Soultanov, Chairman of Solagran and inventor on the patent with Solagran's Professor Viktor Roschin, said "The granting of our core technology patent in the US is a very important milestone for Solagran. It establishes our proprietary position in the manufacture from different plant species of high-purity polyprenols and other products across major jurisdictions, and gives us a firm foundation for future commercial success".

Polyprenols are present in plants in low concentration and are naturally-occurring precursors of dolichols. Dolichols exist primarily in animals and are found in all key organs of the human body, playing a major role in crucial metabolic pathways, protecting cellular membranes, stabilising cell proteins and supporting the body's immune system. Dolichol deficit or deficiencies are observed with degenerative diseases including chronic inflammatory conditions and cognitive disorders.

Importantly, polyprenols can be administered orally and are transformed in the liver to dolichols. This provides a strong rationale for polyprenol supplementation to potentially address multiple conditions, including inflammatory diseases, cognitive decline and multiple liver conditions.

Until development of the Solagran manufacturing process it had not been possible to extract polyprenols in commercial quantities at reasonable cost. Live conifer needles are one of the richest and most widely-available sources for polyprenol extraction worldwide. Solagran uses conifer needles as the starting material for its patented extraction process and has constructed the world's first manufacturing facility for the production of commercial quantities of pharmaceutical grade polyprenols.

Solagran is currently in negotiations to secure distribution for products containing its proprietary polyprenols in selected countries, and is also preparing registration documentation for new territories.

About Solagran

Solagran Ltd is a Melbourne-based biotechnology company. It manufactures and markets a range of unique, efficacious and proprietary products sourced from different species of conifer trees, targeting the fast-growing natural healthcare and nutraceutical sectors. Solagran's competitive advantage in the sector is its long history of scientific excellence, academic credibility and proprietary manufacturing innovations. The company's products range from registered pharmaceuticals, to supplements, nutraceuticals and over-the-counter products. Solagran products are marketed in Australia, Russia, Malaysia and the UAE, and additionally registered in Indonesia and Singapore, with negotiations underway to expand into new territories.

Dr. Vagif Soultanov
Chairman
Solagran Limited